It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
HIV Pre-exposure Prophylaxis (PrEP) uptake among transgender (TG) people and gay men and other men who have sex with men (MSM) remains low, despite South Africa being the first African country to approve PrEP. This mixed-methods study used a two-phase explanatory sequential design: (1) quantitative analysis of cross-sectional surveys followed by (2) qualitative in-depth interviews. This study explored facilitators and barriers to PrEP uptake to identify strategies to increase utilization in these key populations. We conducted 202 cross-sectional surveys and 20 in-depth interviews between July 2021 and March 2022 in Soshanguve, Tshwane, Gauteng. Quantitative data were analyzed using univariate logistic regression; thematic analysis was performed for qualitative data. Findings show high willingness to use PrEP but low PrEP uptake. We outline strategies to facilitate PrEP use: (1) demystify daily PrEP by deploying community-engaged PrEP education campaigns; (2) capitalize on existing peer networks; and (3) expand accessible and culturally responsive PrEP service delivery models. We provide feasible recommendations to close the PrEP uptake gap in these key populations in South Africa.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of California San Francisco School of Medicine, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 Setshaba Research Centre, Tshwane, South Africa (GRID:grid.477887.3)
3 South African Medical Research Council, Biostatistics Research Unit, Cape Town, South Africa (GRID:grid.415021.3) (ISNI:0000 0000 9155 0024)
4 University of Witwatersrand, Perinatal HIV Research Unit, Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135); Wits Health Consortium, African Social Sciences Unit of Research and Evaluation (ASSURE), Johannesburg, South Africa (GRID:grid.11951.3d) (ISNI:0000 0004 1937 1135); South African Medical Research Council, Health Systems Research Unit, Bellville, South Africa (GRID:grid.415021.3) (ISNI:0000 0000 9155 0024)
5 Setshaba Research Centre, Tshwane, South Africa (GRID:grid.477887.3); University of Pretoria, Department of Medical Microbiology, Tshwane, South Africa (GRID:grid.49697.35) (ISNI:0000 0001 2107 2298)